GlobeNewswire Inc.··NaIMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress
$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.
IMNNPhase 3 clinical trialfinancial results